Patient demographics and clinical characteristics
| Patient characteristics* N=90 | |
| Age, mean (SD) [median], years | 67.1 (8.0) [68] |
| Male, n (%) | 52 (57.8) |
| Female, n (%) | 38 (42.2) |
| Race and ethnicity, n (%) | |
| White | 84 (93.3) |
| African American | 4 (4.4) |
| Asian | 1 (1.1) |
| American Indian/Alaskan Native | 4 (1.1) |
| Non-Hispanic, n (%) | 89 (98.9) |
| Height, mean (SD), cm | 168.7 (10.9) |
| Weight, mean (SD), kg | 76.6 (11.6) |
| Medical/drug insurance, n (%) | |
| Commercial/private | 43 (47.8) |
| Medicaid | 9 (10.0) |
| Medicare | 38 (42.2) |
| Tumor characteristics* | n (%) |
| Stage of diagnosis at the time of avelumab initiation | |
| IIIB | 16 (17.8) |
| IV | 74 (82.2) |
| Location of primary tumor† | |
| Face | 8 (8.9) |
| Lower limb/trunk | 34 (37.8) |
| Scalp and neck | 27 (30) |
| Upper limb | 20 (22.2) |
| Unknown | 5 (5.6) |
| Other | 1 (1.1) |
| Sites of distant metastasis‡ | |
| Lymph nodes | 60 (66.7) |
| Distant skin | 24 (26.7) |
| Lung | 47 (52.2) |
| Bone | 14 (15.6) |
| Liver | 31 (34.4) |
| Brain | 1 (1.1) |
| Other | 2 (2.2) |
| Merkel cell polyomavirus | |
| Positive | 34 (37.8) |
| Negative | 9 (10.0) |
| Unknown | 47 (52.2) |
| PD-L1 status | |
| Positive | 32 (35.6) |
| Negative | 3 (3.3) |
| Unknown | 55 (61.1) |
| ECOG PS | |
| 0 | 0 |
| 1 | 28 (31.1) |
| 2 | 38 (42.2) |
| 3 | 23 (25.6) |
| 4 | 1 (1.1) |
| 5 | 0 |
| Comorbid conditions‡ | n (%) |
| Any comorbidity | 41 (45.6) |
| Individual comorbidities | |
| AIDS (not only HIV positive) | 1 (2.4) |
| Any prior solid tumor (within 5 years of diagnosis) | 1 (2.4) |
| Autoimmune condition, other | 2 (4.8) |
| Cerebrovascular disease | 6 (14.3) |
| Chronic obstructive pulmonary disease | 11 (26.2) |
| Congestive heart failure | 7 (16.7) |
| Connective tissue disease | 3 (7.1) |
| Coronary artery disease | 16 (38.1) |
| Dementia | 1 (2.4) |
| Diabetes with organ damage | 5 (11.9) |
| Diabetes (no complications) | 10 (23.8) |
| Hemiplegia or paraplegia | 0 |
| Hepatitis | 0 |
| Leukemia | 1 (2.4) |
| Lymphoma | 0 |
| Mild liver disease | 3 (7.1) |
| Moderate-to-severe liver disease | 1 (2.4) |
| Moderate-to-severe renal disease | 2 (4.8) |
| Peptic ulcer disease | 2 (4.8) |
| Peripheral vascular disease | 5 (11.9) |
| Other | 1 (2.4) |
*On index date.
†Not mutually exclusive.
‡Pre-index period.
ECOG PS, Eastern Cooperative Oncology Group performance status; PD-L1, programmed death-ligand 1.